# Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

> **NCT01552356** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 54 (actual)

## Conditions studied

- Solid Neoplasm

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Pazopanib Hydrochloride
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01552356
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-03-19
- **Primary completion:** 2015-12-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01552356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01552356, "Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01552356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*